BioCentury
ARTICLE | Clinical News

Imeglimin: Completed Phase IIb enrollment

July 18, 2016 7:00 AM UTC

Poxel completed enrollment of about 304 treatment-naive and pre-treated patients in a double-blind, placebo-controlled, Japanese Phase IIb trial evaluating 500, 1,000 and 1,500 mg oral imeglimin for 2...